On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
Japan Aims for 80% Generic Share in All Prefectures by FY2023-End: Honebuto Draft
To read the full story
Related Article
- Japan OKs 2021 Fiscal Policy Blueprint, Vows Transparency in Drug Pricing
June 21, 2021
- Honebuto Text to Add Line for “Transparency and Predictability” of Drug Pricing System
June 16, 2021
- LDP Flags 80% Generic Target for All Prefectures: Honebuto Debate
June 11, 2021
- Govt Unveils Draft Honebuto Paper for 2021, Cabinet OK Expected after Party Tweaks
June 10, 2021
- MHLW to Set New Generic Target of 80% in Every Prefecture by FY2023-End
April 30, 2021
REGULATORY
- Japan Govt Sued for Lack of Information on COVID Vaccine Risks
April 18, 2024
- MOF Ramps Up Push for Use of Cost-Effectiveness Assessment in Reimbursement Decisions
April 17, 2024
- PMDA Stepping Up Generic Compliance Inspections from August Approvals
April 16, 2024
- 14 Makers Picked for Health Minister-Championed Subsidy Program for Cough Meds, Essential Drugs
April 15, 2024
- Japan to Discuss Orphan Designation for Cannabidiol, 2 More Drugs
April 15, 2024
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…